JP2023502267A5 - - Google Patents
Info
- Publication number
- JP2023502267A5 JP2023502267A5 JP2022529553A JP2022529553A JP2023502267A5 JP 2023502267 A5 JP2023502267 A5 JP 2023502267A5 JP 2022529553 A JP2022529553 A JP 2022529553A JP 2022529553 A JP2022529553 A JP 2022529553A JP 2023502267 A5 JP2023502267 A5 JP 2023502267A5
- Authority
- JP
- Japan
- Prior art keywords
- blocking antibody
- composition according
- ccr9
- tnfα blocking
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962938795P | 2019-11-21 | 2019-11-21 | |
| US62/938,795 | 2019-11-21 | ||
| US16/740,861 US10792360B1 (en) | 2019-11-21 | 2020-01-13 | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| US16/740,861 | 2020-01-13 | ||
| US17/064,550 | 2020-10-06 | ||
| US17/064,550 US20210154292A1 (en) | 2019-11-21 | 2020-10-06 | Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies |
| PCT/US2020/061569 WO2021102302A1 (en) | 2019-11-21 | 2020-11-20 | Compositions and methods for treating ccr9-mediated diseases using ccr9 inhibitor and anti-tnf-alpha blocking antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502267A JP2023502267A (ja) | 2023-01-23 |
| JP2023502267A5 true JP2023502267A5 (https=) | 2023-11-27 |
Family
ID=75974977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022529553A Withdrawn JP2023502267A (ja) | 2019-11-21 | 2020-11-20 | ＣＣＲ９阻害剤および抗ＴＮＦ－α遮断抗体を使用してＣＣＲ９媒介性疾患を治療するための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210154292A1 (https=) |
| EP (1) | EP4061365A4 (https=) |
| JP (1) | JP2023502267A (https=) |
| KR (1) | KR20220103980A (https=) |
| CN (1) | CN115209896A (https=) |
| AU (1) | AU2020386066A1 (https=) |
| BR (1) | BR112022009638A2 (https=) |
| CA (1) | CA3159127A1 (https=) |
| IL (1) | IL293133A (https=) |
| MX (1) | MX2022006071A (https=) |
| WO (1) | WO2021102302A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI904146B (zh) | 2020-03-31 | 2025-11-11 | 美商卡默森屈有限公司 | 使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法 |
| CN116492341B (zh) * | 2023-05-19 | 2025-04-15 | 广州市红十字会医院 | 维塞诺在制备治疗白癜风药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ566263A (en) * | 2002-05-24 | 2009-09-25 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| WO2014088113A1 (en) * | 2012-12-04 | 2014-06-12 | Millennium Pharmaceuticals, Inc. | Prophylactic or therapeutic method for sjogren's syndrome using specific ccr9 receptor inhibitors/antagonists |
| DK3126330T3 (en) * | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| WO2016057424A1 (en) * | 2014-10-06 | 2016-04-14 | Chemocentryx, Inc. | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies |
| EP3554541B1 (en) * | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| US10792360B1 (en) * | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| TWI904146B (zh) * | 2020-03-31 | 2025-11-11 | 美商卡默森屈有限公司 | 使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法 |
-
2020
- 2020-10-06 US US17/064,550 patent/US20210154292A1/en not_active Abandoned
- 2020-11-20 CN CN202080094015.2A patent/CN115209896A/zh active Pending
- 2020-11-20 EP EP20890027.4A patent/EP4061365A4/en not_active Withdrawn
- 2020-11-20 MX MX2022006071A patent/MX2022006071A/es unknown
- 2020-11-20 WO PCT/US2020/061569 patent/WO2021102302A1/en not_active Ceased
- 2020-11-20 CA CA3159127A patent/CA3159127A1/en active Pending
- 2020-11-20 BR BR112022009638A patent/BR112022009638A2/pt not_active IP Right Cessation
- 2020-11-20 JP JP2022529553A patent/JP2023502267A/ja not_active Withdrawn
- 2020-11-20 IL IL293133A patent/IL293133A/en unknown
- 2020-11-20 AU AU2020386066A patent/AU2020386066A1/en not_active Abandoned
- 2020-11-20 KR KR1020227019228A patent/KR20220103980A/ko not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11607411B2 (en) | Methods of treating Crohn's disease and ulcerative colitis | |
| JP2017530163A5 (https=) | ||
| JP2023502267A5 (https=) | ||
| JP2024094370A5 (https=) | ||
| JP2025176106A (ja) | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 | |
| JP7142200B2 (ja) | ＭＡｄＣＡＭアンタゴニストの投与レジメン | |
| JP2023509790A (ja) | α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法 | |
| JP2017113019A5 (https=) | ||
| RU2015141418A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| JP6081699B2 (ja) | Ｉｌ−２８ｂの分析方法 | |
| JP2019519533A5 (https=) | ||
| CN107001467A (zh) | C‑c趋化因子受体9型(ccr9)的抑制剂和抗alha4beta7整联蛋白阻断抗体的组合治疗 | |
| JP2010280659A (ja) | 肝疾患の診断及び治療 | |
| CA2750952A1 (en) | Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders | |
| JP2022529929A5 (https=) | ||
| JP2020522535A5 (https=) | ||
| JP2019523764A5 (https=) | ||
| JP2021522255A5 (https=) | ||
| RU2020131402A (ru) | 4-метилдигидропиримидиноновые соединения и их применение в фармацевтике | |
| JP2023502267A (ja) | ＣＣＲ９阻害剤および抗ＴＮＦ－α遮断抗体を使用してＣＣＲ９媒介性疾患を治療するための組成物および方法 | |
| PE20230516A1 (es) | Composiciones y metodos para tratar la enfermedad intestinal inflamatoria mediante el uso de inhibidor de ccr9 y anticuerpos bloqueadores anti-il-23 | |
| JP2022550390A5 (https=) | ||
| JP2022518527A5 (https=) | ||
| JP7629448B2 (ja) | クローン病の予防および治療に使用するためのレバミピド含有医薬組成物 | |
| JP2007531733A5 (https=) |